CROI 2016 Program at a Glance

Program and Agenda

432 Minimal Removal of Dolutegravir by Hemodialysis in HIV-Infected Patients José Moltó 1 ; Fredzzia Graterol 2 ; Cristina Miranda 1 ; Ioana Bancu 2 ; Saye Khoo 3 ; Alieu Amara 3 ; Anna Bonjoch 1 ; Bonaventura Clotet 1 1 LluitaContra laSIDAFndn,GermansTrias iPujolUnivHosp,Barcelona, Spain; 2 HospUniversitariGermansTrias iPujol,Badalona,Spain; 3 Univof Liverpool,Liverpool,UK 433 A Comparison of the Pharmacokinetics of Efavirenz During Pregnancy and Postpartum Stein Schalkwijk 1 ; Brookie M. Best 2 ; Angela Colbers 1 ; Alice Stek 3 ; JiajiaWang 4 ; David Hawkins 5 ; Mark Mirochnick 6 ; David M. Burger 1 ; for the International Maternal Pediatric Adolescent AIDS ClinicalTrials (IMPAACT) P1026s ProtocolTeam, and the Pharmacokinetics of Newly Developed Antiretroviral Agents in HIV-infected PregnantWomen (PANNA) Study Network 1 RadboudUnivMedCntr,Nijmegen,Netherlands; 2 UnivofCaliforniaSan Diego,SanDiego,CA,USA; 3 UnivofSouthernCalifornia,LosAngeles,CA, USA; 4 HarvardSchofPH,Boston,MA,USA; 5 ChelseaandWestminster HospNHSFndnTrust,London,UK; 6 BostonUnivSchofMed,Boston, MA,USA 434 Contamination of Herbal Medicines With ARVs and Widespread Use by PLWH in Nigeria Joshua Gini 1 ; Bala I. Harri 2 ; Elkanah D. Kabilis 3 ; Mark Stevens 4 ; Paul P. Pama 5 ; Alieu Amara 1 ; Dilly P. Sujan 1 ; Justin Chiong 1 ; Saye Khoo 1 ; for the Pharmacology Research Laboratories University of Liverpool 1 UnivofLiverpool,Liverpool,UK; 2 DalhatuArafSpecialistHosp,Lafia, NassarawaState,Lafia,Nigeria; 3 GombeStateSpecialistHosp,Gombe, Nigeria; 4 FaithAliveFndn, JosPlateauState,Nigeria; 5 FedMedCntr Katsina,Katsina,Nigeria 435 TDF/EVG Nanoparticle Formulation: Plasma Pharmacokinetics in Humanized Mice Christopher Destache ; Subhra Mandal CreightonUniv,Omaha,NE,USA 436 Antiretroviral Drug Use in a Cross-sectional Population Survey in Africa: HPTN 043 Jessica M. Fogel 1 ;William Clarke 1 ; Michal Kulich 2 ; Estelle Piwowar- Manning 1 ; Glenda Gray 3 ; Linda Richter 4 ; Heidi van Rooyen 5 ;Thomas Coates 6 ; Susan H. Eshleman 1 ; for the For the HPTN 043 (NIMH Project Accept) StudyTeam 1 JohnsHopkinsUnivSchofMed,Baltimore,MD,USA; 2 CharlesUniv, Prague,CzechRepublic; 3 SouthAfricanMedRsrCouncil,CapeTown, SouthAfrica; 4 Univof theWitwatersrand, Johannesburg,SouthAfrica; 5 HumanScisRsrCouncil,Durban,SouthAfrica; 6 UnivofCaliforniaLos Angeles,LosAngeles,CA,USA 437LB A Single Monotherapy Dose of MK-8591, a Novel NRTI, Suppresses HIV for 10 Days Evan Friedman 1 ; Dirk Schuermann 2 ; Deanne J. Rudd 3 ; Sabrina Fox-Bosetti 3 ; Sandra Zhang 3 ; Martine Robberechts 3 ; Andreas Hueser 4 ; Daria J. Hazuda 5 ; Marian Iwamoto 6 ; Jay Grobler 5 ; for the HIV Early DevelopmentTeam 1 Merck&Co, Inc,Rahway,NJ,USA; 2 CharitéRsrOrganisationGmbH, Berlin,Germany; 3 Merck&Co., Inc,Kenilworth,NJ,USA; 4 Charité UniversitätsmedizinBerlin,Germany,RsrHosp,Berlin,Germany; 5 Merck &Co, Inc,WestPoint,PA,USA; 6 Merck&Co, Inc,Kenilworth,NJ,USA

Session P-L1 Poster Abstracts

Hall A/B

2:45 PM-4:00 PM HIV Drug Resistance: Surveillance and Transmission 477 HIV Pretreatment Drug Resistance in Mexico: A Nationally RepresentativeWHO Survey S antiago Avila-Rios 1 ; Claudia García-Morales 1 ; DanielaTapia-Trejo 1 ; Margarita Matías-Florentino 1 ;Verónica Quiroz-Morales 1 ; Jesús Casillas- Rodríguez 2 ; Juan Sierra-Madero 3 ; Eddie León 4 ; Carlos Magis 4 ; Gustavo ReyesTeran 1 ; for the HIV Drug Resistance Mexican Network Group 1 Natl InstofRespiratoryDiseases,MexicoCity,Mexico; 2 Condesa SpecialisedClinic,MexicoCity,Mexico; 3 Natl InstofMedScisand NutritionSalvadorZubirán,MexicoCity,Mexico; 4 NatlCntr forHIV/AIDS PreventionandControl,MexicoCity,Mexico 478 The Dynamics of Drug Resistance Detected During Acute HIV Infection Ruth M. Kanthula 1 ; JulieWeis 2 ; ChrisWarth 2 ; Nelly R. Mugo 3 ; Lisa Frenkel 4 ; Connie M. Celum 1 ; Julie M. Overbaugh 2 ; Frederick Matsen 2 ; Jared M. Baeten 1 ; Dara Lehman 2 1 UnivofWashington,Seattle,WA,USA; 2 FredHutchinsonCancerRsrCntr, Seattle,WA,USA; 3 KenyaMedRsr Inst,Thika,Kenya; 4 SeattleChildren's Rsr Inst,Seattle,WA,USA 479LB HIV-1 InfectionWith Multiclass Resistance Despite Preexposure Prophylaxis (PrEP) David C. Knox 1 ; Darrell H.Tan 2 ; P. Richard Harrigan 3 ; Peter L. Anderson 4 1 MapleLeafMedClinic,Toronto,ON,Canada; 2 StMichael’sHosp,Toronto, ON,Canada; 3 BCCntr forExcellence inHIV/AIDS,Vancouver,BC,Canada; 4 UnivofColorado,Denver,CO,USA 480 Large Cluster Clinical Isolates Show Facilitated Escape From Integrase Inhibitors Bluma G. Brenner 1 ; Maureen Oliveira 1 ; Ruxandra Ilinca Ibanescu 1 ; Olga Golubkov 1 ; Bonnie A. Spira 2 ; Mark A.Wainberg 2 1 LadyDavis Inst,Montreal,QC,Canada; 2 McGillUnivAIDSCntr,Montreal, QC,Canada 481 An Informatics Approach to Predicting Rates of Transmitted HIV-1 Drug Resistance Joseph M.Volpe 1 ; DongmeiYang 1 ; Suqin Cai 1 ; JayTimmerman 2 ; Charles M.Walworth 1 ; Jeannette M.Whitcomb 1 1 MonogramBioScis,SouthSanFrancisco,CA,USA; 2 LabCorp Informatics, Durham,NC,USA 482 Impact of Transmitted Thymidine Analogue Mutations on Responses to First-Line ART Anna Maria Geretti 1 ; EllenWhite 2 ; Apostolos Beloukas 3 ; Chloe Orkin 4 ; AnnaTostevin 2 ; PeterTilston 5 ; David Chadwick 6 ; Caroline Sabin 7 ; David Dunn 2 ; for the HIV Drug Resistance Database and CHIC Study 1 Instof Infection&GlobalHlth,UnivofLiverpool,Liverpool,UK; 2 Med RsrCouncilClinicalTrialsUnitatUnivCollLondon,London,UK; 3 Univof Liverpool,Liverpool,UK; 4 BartsHlthNHSTrust,London,UK; 5 Manchester Royal Infirmary,Manchester,UK; 6 SouthTeesHospNHSFndnTrust, Middlesbrough,UK; 7 UnivCollLondon,London,UK

Poster Listings

60

CROI 2016